Report Categories
View AllRecent Articles
View All
FENC Fennec Pharmaceuticals posts far wider than expected Q4 2025 loss even as shares tick higher
DMA Destra Multi Q2 loss widens revenue tumbles 166 as alternative fund faces market headwinds
FedEx Corporation FDX Valuation Assessment Following a 12Month 889 Share Price Rally
MLACR Mountain quarterly filing shows no revenue as acquisition pipeline remains central focus for SPAC investors